Pre‐treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma

Abstract

To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2-year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).

The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation

“…There is growing evidence that prognostic scores based on general inflammatory activity have a major impact on clinical outcome in various malignancies. Within the context of optimal risk stratification for other malignant haematological neoplasms, such as diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma, or colorectal carcinomas, systemic inflammatory scores have proven helpful [16][17][18][19][20][21][22]. These risk scores incorporate metabolic and inflammatory parameters of peripheral Cancers 2020, 12, 921 3 of 18 blood since the immunological and inflammatory response has a considerable impact on the tumour microenvironment and the progress of malignant diseases and correlates with outcome in tumour patients [16].…”

Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients

“…The role of immune system before therapy is increasingly recognised to determine the general condition of immune surveillance against malignant diseases or prognosis. Pretreatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio was shown to be prognostic of progression in early stage HL . Current renaissance in immunotherapy will subsequently influence the treatment results and possibly the risk of SC, similarly as in novel treatment approaches in solid cancers …”

“…Pretreatment neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio was shown to be prognostic of progression in early stage HL. 16 Current renaissance in immunotherapy will subsequently influence the treatment results and possibly the risk of SC, similarly as in novel treatment approaches in solid cancers. 5,17,18 On the basis of our initial analysis of HL survivors, 19 we suggested special follow-up schema for patients after initial HL treatment and utilised this approach in last decade finding it possible, effective and 21 one may expect reduced risk of radiotherapy induced SC in the future.…”

Differential activation of pro‐survival pathways in response to CD40LG/IL4 stimulation in chronic lymphocytic leukaemia cells

“…From a clinicopathological perspective this is especially apparent in cHL, with scarce malignant cells embedded in a multifaceted inflammatory environment (Skinnider & Mak, 2002). GPS was recently shown to predict outcome in B cell lymphoma (Hao et al, 2017), whereas only NLR and PLR were established as prognosticators in cHL (Marcheselli et al, 2017;Reddy et al, 2017).…”

“…There is growing evidence of a drastic impact of GPS on outcome in various malignancies, including lymphoma and solid tumours (Hao et al, 2017). A most recent study by Reddy et al (2017) assessed the prognostic capabilities of NLR and PLR in early stage cHL revealing independent adverse prognostic implications of an elevated PLR. Other studies made similar observations for elevated NLR (Marcheselli et al, 2017).…”